300 Participants Needed

Natural History Study for Angelman Syndrome

Recruiting at 12 trial locations
JO
WT
LL
K(
BF
Overseen ByBatsheva Friedman, MA
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: Boston Children's Hospital
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to better understand Angelman Syndrome by observing children and adults diagnosed with it. Researchers will gather information from medical professionals and parents to track how the condition changes over time. This knowledge will help improve future treatments. Individuals with a confirmed diagnosis of Angelman Syndrome and no other neurodevelopmental issues may find this trial suitable. As an unphased trial, participation offers a unique opportunity to contribute to foundational research that could lead to better treatments.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Why are researchers excited about this trial?

Researchers are excited about the Angelman Syndrome Natural History Study because it aims to deepen our understanding of Angelman Syndrome by observing the condition's natural progression over time. Unlike treatment-focused studies, this observational study doesn't involve administering new drugs or therapies. Instead, it collects valuable data on how the syndrome affects individuals as they grow, which could lead to better treatment strategies in the future. By providing a clearer picture of the condition's development, this study may pave the way for innovative treatments tailored to the unique needs of those with Angelman Syndrome.

Who Is on the Research Team?

WT

Wen-Hann Tan, BMBS

Principal Investigator

Boston Children's Hospital

Are You a Good Fit for This Trial?

Inclusion Criteria

Molecular diagnosis of Angelman syndrome

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Observation

Participants are observed for developmental, communication, and adaptive skills using various scales

1 year

Follow-up

Participants are monitored for safety and effectiveness after the observation period

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Observational Study

Find a Clinic Near You

Who Is Running the Clinical Trial?

Boston Children's Hospital

Lead Sponsor

Trials
801
Recruited
5,584,000+

Angelman Syndrome Foundation Canada

Collaborator

Trials
1
Recruited
300+

Angelman Syndrome Foundation, Inc.

Collaborator

Trials
2
Recruited
370+

Food and Drug Administration (FDA)

Collaborator

Trials
184
Recruited
1,553,000+

Foundation for Angelman Syndrome Therapeutics Canada

Collaborator

Trials
1
Recruited
300+

Canadian Angelman Syndrome Society

Collaborator

Trials
1
Recruited
300+

Foundation for Angelman Syndrome Therapeutics

Collaborator

Trials
1
Recruited
300+

University of California, San Diego

Collaborator

Trials
1,215
Recruited
1,593,000+

Angelman Syndrome Biomarker & Outcome Measure Consortium (A-BOM)

Collaborator

Trials
1
Recruited
300+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity